## Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

CATALYST PHARMACEUTICAL PARTNERS, INC.

Form 8-K August 14, 2014

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

#### THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 14, 2014

## CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware (State or other jurisdiction of incorporation) 001-33057 (Commission File Number) 76-0837053 (I.R.S. Employer

Identification No.)

355 Alhambra Circle

**Suite 1500** 

Coral Gables, Florida (Address of principal executive offices)

33134

(Zip Code)

Registrant s telephone number, including area code:

(305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

# Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# **Item 8.01 Other Events**

On August 14, 2014, the Company issued a press release announcing its results of operations for the three and six months ended June 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1.

# Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release issued by the Company on August 14, 2014.

2

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.** 

By: /s/ Alicia Grande Alicia Grande

Vice President, Treasurer and CFO

Dated: August 14, 2014